Perioperative Warfarin
(Coumadin) Management
Navigating a fine line
between bleeding and thromboembolic complications
Perioperative
management of the chronically anticoagulated patient is like navigating a fine
line between bleeding versus thromboembolic complications.
INR
The INR is used for monitoring patients who have been stabilized on
Anticoagulant Therapy.
Conventional
Anticoagulation: INR = 2.0 - 3.0
High Intensity
Anticoagulation: INR = 3.0 - 3.5
Any INR >5.0 is
considered a CRITICAL
"Bridging”
is a term used to describe the temporary use of short-acting anticoagulants
(heparin or Low Molecular Weight Heparin, LMWH) during the pause of warfarin
therapy.
LMWH
available in the US: dalteparin (Fragmin®) and enoxaparin
(Lovenox®).
CHAD
SCORE
C
Congestive Heart
failure
1
H
Hypertension
1
A
Age >75 years
1
D
Diabetes
1
S2
Stroke or TIA
2
SCORE
0
3%
Low
1
4%
Low
2
5%
Intermediate
3
6%
Intermediate
4
8%
High
5
12%
High
6
18%
High
CHAD-VASc
SCORE
C
CHF/LV dysfunction
1
H
Hypertension
1
A2
Age ≥ 75
2
D
Diabetes mellitus
1
S2
Stroke/TIA/TE
(thromboembolism)
2
V
Vascular disease -
CAD, MI, PAD or aortic plaque
1
A
Age 65-74
1
Sc
Sex category -
Female
1
Bridging-decision making steps
Step1:
Patient Assesment:
Patient assesment is the first step in every therapy management including
bridging.
Some assessment factors include
1. Patient age
2. Surgery
3. Comorbidities
4. INR and
anticoagulation data
5. Other medications
6. CHADS2 score
Step 2:
Identify the risk of
clot formation.
Low risk: No need of
bridging
Intermediate risk:
Individualize and decide based on patient-specific factors
High-risk:
Consider bridging
Perioperative Warfarin
(Coumadin) Management
Navigating a fine line
between bleeding and thromboembolic complications
Perioperative
management of the chronically anticoagulated patient is like navigating a fine
line between bleeding versus thromboembolic complications.
INR
The INR is used for monitoring patients who have been stabilized on
Anticoagulant Therapy.
Conventional
Anticoagulation: INR = 2.0 - 3.0
High Intensity
Anticoagulation: INR = 3.0 - 3.5
Any INR >5.0 is
considered a CRITICAL
"Bridging”
is a term used to describe the temporary use of short-acting anticoagulants
(heparin or Low Molecular Weight Heparin, LMWH) during the pause of warfarin
therapy.
LMWH
available in the US: dalteparin (Fragmin®) and enoxaparin
(Lovenox®).
CHAD
SCORE
C
|
Congestive Heart
failure
|
1
|
H
|
Hypertension
|
1
|
A
|
Age >75 years
|
1
|
D
|
Diabetes
|
1
|
S2
|
Stroke or TIA
|
2
|
SCORE
0
|
3%
|
Low
|
1
|
4%
|
Low
|
2
|
5%
|
Intermediate
|
3
|
6%
|
Intermediate
|
4
|
8%
|
High
|
5
|
12%
|
High
|
6
|
18%
|
High
|
CHAD-VASc
SCORE
C
|
CHF/LV dysfunction
|
1
|
H
|
Hypertension
|
1
|
A2
|
Age ≥ 75
|
2
|
D
|
Diabetes mellitus
|
1
|
S2
|
Stroke/TIA/TE
(thromboembolism)
|
2
|
V
|
Vascular disease -
CAD, MI, PAD or aortic plaque
|
1
|
A
|
Age 65-74
|
1
|
Sc
|
Sex category -
Female
|
1
|
Bridging-decision making steps
Step1:
Patient Assesment:
Patient assesment is the first step in every therapy management including
bridging.
Some assessment factors include
1. Patient age
2. Surgery
3. Comorbidities
4. INR and
anticoagulation data
5. Other medications
6. CHADS2 score
Step 2:
Identify the risk of
clot formation.
Low risk: No need of
bridging
Intermediate risk:
Individualize and decide based on patient-specific factors
High-risk:
Consider bridging
Comments
Post a Comment